Common Contracts
39 similar Registration Rights Agreement contracts by Aeglea BioTherapeutics, Inc., Bellicum Pharmaceuticals, Inc, Evofem Biosciences, Inc., others
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 24th, 2024 • Entrada Therapeutics, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of June 24, 2024 by and between Entrada Therapeutics, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 28th, 2024 • Immunocore Holdings PLC • Biological products, (no disgnostic substances) • New York
This Registration Rights Agreement (this “Agreement”) is made as of May 28, 2024 by and between Immunocore Holdings plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 18th, 2024 • BICYCLE THERAPEUTICS PLC • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of April 18, 2024 by and between Bicycle Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 15th, 2024 • Contineum Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Registration Rights Agreement (this “Agreement”) is made as of July 9, 2021 by and between Pipeline Therapeutics, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 28th, 2024 • vTv Therapeutics Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of February 27, 2024 by and between vTv Therapeutics Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 15th, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of March 16, 2021 by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 8th, 2023 • Madrigal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of August 7, 2023 by and between Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 3rd, 2023 • Kala Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of March 2, 2023 by and between Kala Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 5th, 2022 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of July 3, 2022 by and between Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 8th, 2021 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances) • New York
This Registration Rights Agreement (this “Agreement”) is made as of September 7, 2021 by and between bluebird bio, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 23rd, 2021 • TScan Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Registration Rights Agreement (this “Agreement”) is made as of January 15, 2021 by and between TScan Therapeutics, Inc., a Delaware corporation (the “Company”), and the person(s) listed on the attached Schedule A who are signatories to this Agreement (each, an “Investor”, and collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 30th, 2021 • Talis Biomedical Corp • Laboratory analytical instruments • New York
This Registration Rights Agreement (this “Agreement”) is made as of March 26, 2021 by and between Talis Biomedical Corporation, a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 18th, 2021 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of March 16, 2021 by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 4th, 2021 • Prelude Therapeutics Inc • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of [ ], 2020 by and between Prelude Therapeutics Incorporated, a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 21st, 2020 • Prelude Therapeutics Inc • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of [ ], 2020 by and between Prelude Therapeutics Incorporated, a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 7th, 2020 • IGM Biosciences, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of _________, 2020, by and between IGM BIOSCIENCES, INC., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in the Investor Rights Agreement (as defined below).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 15th, 2020 • Evofem Biosciences, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of October 14, 2020, by and between Evofem Biosciences, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 10th, 2020 • Assertio Holdings, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of May 20, 2020, by and between Assertio Holdings, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 15th, 2020 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This Registration Rights Agreement (this “Agreement”) is made as of July 13, 2020, by and between Idera Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and entities controlled by Pillar Invest Corporation, Cayman Islands limited partnerships, set forth on Schedule A hereto (each an “Investor” and together the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
EX-10.1 4 d22978dex101.htm EX-10.1 REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 5th, 2020 • New York
This Registration Rights Agreement (this “Agreement”) is made as of September 10, 2015, by and between Seattle Genetics, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 27th, 2020 • Evofem Biosciences, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of [●], 2020, by and between Evofem Biosciences, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 16th, 2020 • Zymeworks Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of March 16, 2020 by and among Zymeworks Inc., a British Columbia corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 12th, 2020 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This Registration Rights Agreement (this “Agreement”) is made as of December 23, 2019, by and between Idera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 11th, 2020 • Atreca, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of March 11, 2020, by and between Atreca, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 7th, 2020 • Leap Therapeutics, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of January 3, 2020, by and between Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 7th, 2020 • Leap Therapeutics, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of January 3, 2020, by and between Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 23rd, 2018 • DBV Technologies S.A. • Biological products, (no disgnostic substances) • New York
This Registration Rights Agreement (this “Agreement”) is made as of March 23, 2018, by and between DBV Technologies S.A., a French Société Anonyme (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 1st, 2017 • Invitae Corp • Services-medical laboratories • New York
This Amended and Restated Registration Rights Agreement (this “Agreement”) is made as of July 31, 2017, by and among Invitae Corporation, a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A, each of whom is an “Investor” (each a “Pre-IPO Investor” and collectively the “Pre-IPO Investors”) under that certain Fifth Amended and Restated Investors’ Rights Agreement made as of August 26, 2014 among the Company and the various Pre-IPO Investors party thereto (as amended to date, the “Prior Agreement”), with each such Pre-IPO Investor listed on the attached Schedule A referred to herein as an “Investor” and collectively as the “Investors.” This Agreement shall be effective, and shall supersede and replace the Prior Agreement, upon execution by the Company and the holders of a majority of the Registrable Securities then outstanding (as defined in the Prior Agreement). Notwithstanding any provision herein to the contrary, the Company may unilaterally amend
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 17th, 2017 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Registration Rights Agreement (this “Agreement”) is made as of March 15, 2017, by and between BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 20th, 2016 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of September 19, 2016, by and between Aquinox Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 9th, 2016 • Genomic Health Inc • Services-medical laboratories • New York
This Registration Rights Agreement (this “Agreement”) is made as of August 8, 2016, by and between Genomic Health, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 14th, 2016 • Bellicum Pharmaceuticals, Inc • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of January 15, 2016, by and between Bellicum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 12th, 2016 • Incyte Corp • Services-commercial physical & biological research • New York
This Registration Rights Agreement (this “Agreement”) is made as of February 12, 2016, by and between Incyte Corporation, a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 15th, 2016 • Bellicum Pharmaceuticals, Inc • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of January 15, 2016, by and between Bellicum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 7th, 2016 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of January 6, 2016, by and between ACADIA Pharmaceuticals Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
